Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 23 November 2016Published date: 26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 22 July 2015
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 22 July 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 25 June 2014
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 November 2013
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 February 2013
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 23 July 2008
Dapagliflozin, in combination with insulin, for treating type 1 diabetes [ID1478]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 August 2019
Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 December 2019
Diabetic retinopathy - ruboxistaurin [ID382]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Diabetes - buccal insulin [ID311]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes (ID1450)Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes [ID1451]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab for treating diabetic retinopathy [ID1592]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC